Administration of the proinflammatory molecule lipopolysaccharide (LPS) alters transport rates for many peptides across the blood-brain barrier (BBB). We and others have previously shown that effects of LPS on BBB transport are highly dependent on the injection paradigm used, and timing of the study. Cytokine expression in both brain and serum compartments influences the BBB response to an inflammatory stimulus, and mediates changes in BBB transport. Here, we used multianalyte technology to simultaneously determine the responses of 13 cytokines and chemokines (G-CSF, GM-CSF, IL-1a, IL-1b, IL-6, IL-10, IL-13, IP-10, KC, MCP-1, MIP-1a, RANTES, and TNF-a) in brain and blood to single and repeated injections of LPS and path analysis to determine the major relations among these analytes. Major findings are: (1) in comparison to measurements taken from a time course after a single injection of LPS, the three injection regimen of LPS produced significantly higher levels in brain for G-CSF, IL-1a, IL-6, MCP-1, MIP-1a, and TNF and in serum for G-CSF, IL-6, and GM-CSF and (2) path analysis distinguished direct from indirect correlations between analyte pairs, with MCP-1, IL-6, G-CSF, and KC mediating relations among these cytokines both within and between serum and brain compartments. These results suggest that potentiation of cytokine levels in brain and serum compartments could play important roles in the regulation of BBB transport, and that our novel application of an established statistical method can be used to assess direct correlations within multiplexed datasets.
Introduction
The blood-brain barrier (BBB) is an important part of the central nervous system whose primary functions include regulation of the permeation of molecules between the brain and circulation. The BBB accomplishes this by both restricting passage of potentially harmful circulating molecules through expression of intercellular tight junctions and lowered rates of macropinocytosis while promoting passage of nutrients and regulatory peptides through expression of specific transporters (Abbott et al., 2010) . Alterations in BBB transport have been implicated in a number of diseases affecting the CNS, including obesity, diabetes, Alzheimer's disease, and neuro-AIDS (Banks, 2008; Banks et al., 2006; Castaneda et al., 2010; Horani and Mooradian, 2003; Zlokovic et al., 2010) . Many of these transporters also show altered functions under inflammatory conditions, suggesting that inflammation could influence the course of disease through its actions at the BBB. Peripheral injection of lipopolysaccharide (LPS) is one model of systemic inflammation which has routinely been used to study alterations in BBB transport. We and others have shown that a peripheral injection of LPS significantly alters BBB transport systems for insulin, leptin, gp120, amyloid beta peptide, PACAP, P-glycoprotein substrates and TNF-a (Banks et al., 1999; Jaeger et al., 2009; Jin et al., 2011; Nonaka et al., 2004 Nonaka et al., , 2005 Osburg et al., 2002; Xaio et al., 2001) . Notably, temporal patterns of altered transporter function differed depending on the peptide studied (Nonaka et al., 2004; Xaio et al., 2001) . It was also found in some of these studies that repeated injection of LPS was more effective at altering BBB transport of these molecules than a single injection (Banks et al., 1999; Nonaka et al., 2005; Xaio et al., 2001) . The mechanisms behind both of these effects remain to be understood, but likely involve changes in inflammatory mediators such as cytokines and chemokines.
Addressing the question of how cytokines and chemokines could affect BBB transport in vivo is complex for a number of reasons. First, cytokines and chemokines produced either in the blood or brain compartments, as well as by brain endothelial cells
